Aspects and prospects of preclinical theranostic radiopharmaceutical development

Theranostics. 2024 Oct 7;14(17):6446-6470. doi: 10.7150/thno.100339. eCollection 2024.

Abstract

This article provides an overview of preclinical theranostic radiopharmaceutical development, highlighting aspects of the preclinical development stages that can lead towards a clinical trial. The key stages of theranostic radiopharmaceutical development are outlined, including target selection, tracer development, radiopharmaceutical synthesis, automation and quality control, in vitro radiopharmaceutical analysis, selecting a suitable in vivo model, preclinical imaging and pharmacokinetic analysis, preclinical therapeutic analysis, dosimetry, toxicity, and preparing for clinical translation. Each stage is described and augmented with examples from the literature. Finally, an outlook on the prospects for the radiopharmaceutical theranostics field is provided.

Keywords: Alpha therapy; Beta therapy; Nuclear Medicine; PET; SPECT; Theranostics.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Development / methods
  • Drug Evaluation, Preclinical / methods
  • Humans
  • Radiopharmaceuticals* / therapeutic use
  • Theranostic Nanomedicine / methods

Substances

  • Radiopharmaceuticals